Skip to main content
SpringerLink
Log in

Do Calcium Antagonists Have a Place in the Treatment of Mood Disorders?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Abdel-Latif AA. Calcium-mobilizing receptors, poly-phosphoino-sitides, and the generation of second messengers. Pharmacological Review 38: 227–272, 1986

    CAS  Google Scholar 

  • Bagchi SP. Antidopaminergic action of verapamil and several other drugs: inactivation of vesicular dopamine. Life Sciences 46: 857, 1990

    Article  PubMed  CAS  Google Scholar 

  • Barrows M, Childs A. An anti-tardive dyskinesia effect of verapamil. Correspondence. American Journal of Psychiatry 143: 1485, 1986

    Google Scholar 

  • Barton BM, Gitlin MJ. Verapamil in treatment-resistant mania. Journal of Clinical Psychopharmacology 7: 101–103, 1987

    Article  PubMed  CAS  Google Scholar 

  • Berlant JL. Verapamil in bipolar and unipolar depression. Abstract 35B. CME Syllabus & Proceedings Summary, American Psychiatric Association 143rd Annual Meeting, p. 177, New York, May 12–17, 1990

  • Brady JP, Price TRP, McAllister TW, Dietrich K. A trial of verapamil in the treatment of stuttering in adults. Biological Psychiatry 25: 626–630, 1989

    Article  Google Scholar 

  • Brotman AV, Farhadi AM, Gelenberg AJ. Verapamil treatment of acute mania. Journal of Clinical Psychiatry 47: 136–138, 1986

    PubMed  CAS  Google Scholar 

  • Buck OD, Havey P. Treatment of tardive dyskinesia with verapamil. Journal of Clinical Psychopharmacology 8: 303–304, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bussche GV, De Beukelaar F, Wauquier A. Calcium entry-blockade and epilepsy. In Godfraind et al. (Eds) Calcium entry blockers and tissue protection, pp. 229–236, Raven Press, New York, 1985

    Google Scholar 

  • Cade JFJ. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 36: 349–352, 1949

    Google Scholar 

  • Caillard V. Treatment of mania using a calcium antagonist. Preliminary trial. Neuropsychobiology 14: 23–26, 1985

    Article  CAS  Google Scholar 

  • Caillard V. Massé traitement de la manie par un inhibiteur calcique: étude préliminaire. Encéphale 8: 587–594, 1982

    PubMed  CAS  Google Scholar 

  • Callewaert G, Hanbauer I, Morad M. Modulation of calcium channels in cardiac and neural cells by an endogenous peptide. Science 243: 663–666, 1989

    Article  PubMed  CAS  Google Scholar 

  • Carman JS, Wyatt RJ. Use of calcitonin in psychotic agitation or mania. Archives of General Psychiatry 36: 72–75, 1979

    Article  PubMed  CAS  Google Scholar 

  • Chouza C, Caamano JL, Aljanati R, Scaramelli A, De Medina O, et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1: 1303–1304, 1986

    Article  PubMed  CAS  Google Scholar 

  • Deicken RF. Verapamil treatment of premenstrual syndrome. Biological Psychiatry 24: 689–692, 1988

    Article  PubMed  CAS  Google Scholar 

  • Del Pozo E, Caro G, Baeyens JM. Analgesic effects of several calcium channel blockers in mice. European Pharmacology 90: 155–160, 1987

    Article  Google Scholar 

  • Doran AR, Narang PK, Meigs CV, Wolkowitz OM, Roy A, et al. Verapamil concentrations in cerebrospinal fluid after oral administration. New England Journal of Medicine 312: 1261–1262, 1985

    PubMed  CAS  Google Scholar 

  • Dose M, Emrich HM. Antimanic properties of verapamil. In Shagass C et al. (Eds) Biological psychiatry 1985, pp. 320–322, Elsevier, New York, 1986

    Google Scholar 

  • Dubovsky SL. Intracellular calcium in affective disorders: evidence in favour of deranged dynamics. In Shagass C et al. (Eds) Biological psychiatry 1985, pp. 317–319, Elsevier, New York, 1986

    Google Scholar 

  • Dubovsky SL. Intracellular calcium and ion disturbances in affective disorders. Abstract 35D. CME Syllabus & Proceedings Summary, American Psychiatric Association, 143rd Annual Meeting, pp. 177-178, New York, May 12–17, 1990

  • Dubovsky SL, Franks RD. Intracellular calcium ions in affective disorders: a review and a hypothesis. Biological Psychiatry 18: 781–797, 1983

    PubMed  CAS  Google Scholar 

  • Dubovsky SL, Franks RD, Allen S. Verapamil: a new antimanic drug with potential interactions with lithium. Journal of Clinical Psychiatry 48: 371–372, 1987

    PubMed  CAS  Google Scholar 

  • Dubovsky SL, Franks RD, Allen S, Murphy J. Calcium antagonists in mania: A double-blind study of verapamil. Psychiatry Research 18: 309–320, 1986

    Article  PubMed  CAS  Google Scholar 

  • Dubovsky SL, Franks RD, Lifschitz ML, Coen P. Effectiveness of verapamil in the treatment of a manic patient. American Journal of Psychiatry 139: 502–504, 1982

    PubMed  CAS  Google Scholar 

  • Dubovsky SL, Franks RD, Schrier D. Phenelzine-induced hypomania: effect of verapamil. Biological Psychiatry 20: 1009–1014, 1985

    Article  PubMed  CAS  Google Scholar 

  • Dunn JM, Groth PE. Verapamil — a once-daily dosage: pharmacokinetic and pharmacodynamic observation. Research 38: 572–578, 1985

    CAS  Google Scholar 

  • Dýcka J, Aufdembrinke B, Rode CP. Efficacy and tolerance of nimodipine in comparison to placebo in 1165 patients with cerebral dysfunction. In Betz E, et al. (Eds) Nimodipine: pharmacological and clinical properties. Proceedings of the 1st International NimotopRSymposium, pp. 319-328, Munich, February 9–11, 1984

  • Fleckenstein A. Specific inhibitors and promotors of calcium action in the excitation-contraction coupling of heart muscle and their role in prevention or production of myocardial lesions. In Harris P & Opie L (Eds) Calcium and the heart, pp. 135–188, Academic Press, London, 1971

    Google Scholar 

  • Gelmers HJ. Nimodipine, a new calcium antagonist in the prophylactic treatment of migraine. Headache 23: 106–109, 1983

    Article  PubMed  CAS  Google Scholar 

  • Gelmers HJ. Nimodipine in ischemic stroke. Clinical Neuropharmacology 10: 412–422, 1987

    Article  PubMed  CAS  Google Scholar 

  • Giannini AJ. Verapamil specificity in mania. Abstract 35A. CME Syllabus & Proceedings Summary, American Psychiatric Association 143rd Annual Meeting, p. 177, New York, May 12–17, 1990

  • Giannini AJ, Houser WL, Loiselle RH, Price WA. Antimanic effects of verapamil. American Journal of Psychiatry 139: 502–504, 1984

    Google Scholar 

  • Giannini AJ, Loiselle RH, Price WA, Giannini MC. Comparison of antimanic efficacy of clonidine and verapamil. Journal of Clinical Pharmacology 25: 307–308, 1985

    PubMed  CAS  Google Scholar 

  • Giannini AJ, Sullivan BS, Folts DJ. Comparison of lithium carbonate, valproic acid and verapamil in the treatment of manic symptoms. Abstract 1. Journal of Clinical Pharmacology (Suppl. 29): 832, 1989

  • Giannini AJ, Taraszewski RS, Loiselle RH. Verapamil and lithium in maintenance therapy of manic patients. Journal of Clinical Pharmacology 27: 980, 1987

    PubMed  CAS  Google Scholar 

  • Gilmore RL, Kasarskis EJ, McAllister RG. Verapamil induced changes in central conduction in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 48: 1140–1146, 1985

    Article  PubMed  CAS  Google Scholar 

  • Gitlin MJ, Weiss J. Verapamil as maintenance treatment of bipolar illness: a case report. Journal of Clinical Psychopharmacology 4: 341–343, 1984

    Article  PubMed  CAS  Google Scholar 

  • Goldstein JA. Nifedipine treatment of Tourette’s syndrome. Correspondence. Journal of Clinical Psychiatry 45: 360, 1984

    CAS  Google Scholar 

  • Goldstein JA. Calcium channel blockers in the treatment of panic disorder. Journal of Clinical Psychiatry 46: 546, 1985

    PubMed  CAS  Google Scholar 

  • Grebb JA, Shelton RC, Taylor EH, Bigelow LB. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia, Biological Psychiatry 21: 691–694, 1986

    Article  PubMed  CAS  Google Scholar 

  • Heinze B, Karrass W, Peters T. Pharmacopsychological effects of flunarizine in geriatric patients with light brainorganic psychosyndrome. European Neurology 25 (Suppl. 1): 115–121, 1986

    Article  PubMed  Google Scholar 

  • Higuishi M, Takenaka F. Effects of verapamil on the transmural energy metabolism in the isoproterenol-induced myokardial lesion. Japanese Heart Journal 19: 913–917, 1978

    Article  Google Scholar 

  • Höschl C. Verapamil for depression? Correspondence. American Journal of Psychiatry 140: 1100, 1983

    PubMed  Google Scholar 

  • Höschl C, Blahoš J, Kabeš J. The use of calcium channel blockers in psychiatry. In Shagass C, et al. (Eds) Biological psychiatry 1985, pp. 329–331, Elsevier, New York, 1986

    Google Scholar 

  • Höschl C, Blahoš J, Taussigová D, Břicháček V, Lukešová J. Má verapamil vliv na psychiku? (in Czech). Československá Psychiatrie 78: 388–391, 1982

    PubMed  Google Scholar 

  • Höschl C, Kozený J. Verapamil in affective disorders: a double-blind, controlled study. Biological Psychiatry 25: 128–140, 1989

    Article  PubMed  Google Scholar 

  • Höschl C, Kozený J. Verapamil in affective disorders. Abstract 35C. CME Syllabus & Proceedings Summary, American Psychiatric Association 143rd Annual Meeting, p. 177, New York, May 12–17, 1990

  • Höschl C, Vacková J, Janda B. Mood stabilizing effect of verapamil. Abstract P-11-4-15. 17th C.I.N.P. Congress, p. 95, Kyoto, September 10–14, 1990

  • Keefe DL, Yee Y-G, Kates RE. Verapamil protein binding in patients and in normal subjects. Clinical Pharmacology and Therapeutics 29: 21–26, 1981

    Article  PubMed  CAS  Google Scholar 

  • Kennedy S, Ozersky S, Robillard M. Refractory bipolar illness may not respond to verapamil. Correspondence. Journal of Psychopharmacology 6: 316–317, 1986

    Article  CAS  Google Scholar 

  • Louis P, Spierings ELH. Comparison of flunarizine (SibeliumR) and pizotifen (SandomigranR) in migraine treatment: a double-blind study. Cephalalgia 2: 197–203, 1982

    Article  PubMed  CAS  Google Scholar 

  • MacPhee GJA, Thompson GG, McInnes GT, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1: 700–703, 1986

    Article  PubMed  CAS  Google Scholar 

  • Markley HG, Cheronis JCD, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 34: 973–976, 1984

    Article  PubMed  CAS  Google Scholar 

  • Martí Massó JF, Obeso JA, Carrera N, Martinez-Lage JM. Aggravation of Parkinson’s disease by cinnarizine. Journal of Neurology, Neurosurgery, and Psychiatry 50: 804–805, 1987

    Article  PubMed  Google Scholar 

  • McCann DJ, Smith CM, Winter JC. A caution against use of verapamil in the treatment of phencyclidine intoxication. Correspondence. American Journal of Psychiatry 143: 679, 1986

    CAS  Google Scholar 

  • McGowan FX, Reiter MJ, Pritchett ELC, Shand DG. Verapamil plasma binding: relationship to alpha1-acid glykoprotein and drug efficacy. Clinical Pharmacology and Therapeutics 33: 485–490, 1983

    Article  PubMed  CAS  Google Scholar 

  • McTavish D, Sorkin EM. Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38: 19–76, 1989

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HL. Lithium mechanisms in bipolar illness and altered intracellular calcium functions. Biological Psychiatry 21: 492–510, 1986

    Article  PubMed  CAS  Google Scholar 

  • Miller RJ. Multiple calcium channels and neuronal function. Science 235: 46–52, 1987

    Article  PubMed  CAS  Google Scholar 

  • Montgomery PT, Mueller ME. Treatment of PCP intoxication with verapamil. Correspondence. American Journal of Psychiatry 142: 882, 1985

    CAS  Google Scholar 

  • Nappi G. Chronic flunarizine treatment in migraine sufferers and the occurrence of depressive phenomena. Giornale di Neuropsicofar-macologia 8: 5, 1986

    Google Scholar 

  • Narang PK, Blumhardt CL, Doran AR, Pickar D. Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia. Clinical Pharmacology and Therapeutics 44: 550–557, 1988

    Article  PubMed  CAS  Google Scholar 

  • Olesen J. Role of calcium entry blockers in the prophylaxis of migraine. European Neurology 25 (Suppl. 1): 72–79, 1986

    Article  PubMed  Google Scholar 

  • Patterson JF. Treatment of acute mania with verapamil. Correspondence. Journal of Clinical Psychopharmacology 7: 206–207, 1987

    Article  CAS  Google Scholar 

  • Pickar D, Wolfowitz OM, Doran AR, Labarca R, Roy A, et al. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Archives of General Psychiatry 44: 113–118, 1987

    Article  PubMed  CAS  Google Scholar 

  • Pickard JD, Walker V, Vile J, Perry S, Smythe PJ, et al. Oral nimodipine reduces prostaglandin and tromboxane production by arteries chronically exposed to a periarterial haematoma and the antifybrinolytic agent tranexamic acid. Journal of Neurology, Neurosurgery and Psychiatry 50: 727–731, 1987

    Article  CAS  Google Scholar 

  • Pileblad E, Carlsson A. In vivo effects of the Ca++antagonist nimodipine on dopamine metabolism in mouses brain. Journal of Neural Transmission 66: 171–187, 1986

    Article  PubMed  CAS  Google Scholar 

  • Pollack MH, Rosenbaum JF. Verapamil in the treatment of recurrent unipolar depression. Biological Psychiatry 22: 779–782, 1987

    Article  PubMed  CAS  Google Scholar 

  • Price WA, Giannini AJ. Verapamil in acute psychosis. Psychosomatics 27: 797, 1986

    Article  PubMed  CAS  Google Scholar 

  • Price WA, Giannini AJ. Use of verapamil in premenstrual tension syndrome. Journal of Clinical Psychiatry 47: 213, 1986a

    PubMed  CAS  Google Scholar 

  • Price WA, Giannini AJ. Neurotoxicity caused by lithium-verapamil synergism. Journal of Clinical Pharmacology 26: 717–719, 1986b

    PubMed  CAS  Google Scholar 

  • Price WA, Giannini AJ. Lithium-verapamil: further considerations. Correspondence. Journal of Clinical Psychiatry 48: 124, 1987

    CAS  Google Scholar 

  • Price WA, Giannini AJ, DiMarzio L. Effectiveness of verapamil in the treatment of premenstrual tension syndrome. Journal of Clinical Pharmacology 25: 455, 1985b

    Google Scholar 

  • Price WA, Giannini AJ, Krishen A. Management of acute PCP intoxication with verapamil. Clinical Toxicology 24: 85–87, 1986

    Article  PubMed  CAS  Google Scholar 

  • Price WA, Giannini AJ, Loiselle RH. Verapamil in the treatment of schizophrenia. Abstract. Journal of Clinical Pharmacology 25: 461, 1985a

    Google Scholar 

  • Price WA, Giannini AJ, Loiselle RH. Treatment of the negative symptoms with verapamil. Abstract. Journal of Clinical Pharmacology 26: 548, 1986a

    Google Scholar 

  • Price WA, Giannini AT, Pascarzi G. Verapamil as an adjunct in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology 26: 546, 1986b

    Google Scholar 

  • Reiter S, Adler L, Angrist B, Peselow E, Rotrosen J. Effects of verapamil on tardive dyskinesia and psychoses in schizophrenia patients. Journal of Clinical Psychiatry 50: 26–27, 1989

    PubMed  CAS  Google Scholar 

  • Ross J, Mackenzie T, Hanson D, et al. Diltiazem for tardive dyskinesia. Correspondence. Lancet 1: 268, 1987

    Article  CAS  Google Scholar 

  • Russi EW, Marchette B, Yerger L, Abraham WM, Ahmed T. Modification of allergic bronchoconstriction by a calcium antagonist: mode of action. American Review of Respiratory Diseases 127: 675–679, 1983

    CAS  Google Scholar 

  • Schou M. Lithium in psychiatric therapy and prophylaxis. Journal of Psychiatric Research 6: 67–95, 1968

    Article  PubMed  CAS  Google Scholar 

  • Snyder SH, Reynolds IJ. Calcium-antagonist drugs: receptor interactions that clarify therapeutic effects. New England Journal of Medicine 313: 995–1002, 1985

    Article  PubMed  CAS  Google Scholar 

  • Solomon L, Williamson P. Verapamil in bipolar illness. Canadian Journal of Psychiatry 31: 442–444, 1986

    CAS  Google Scholar 

  • Triggle DJ. Biochemical pharmacology of calcium blockers. In Flaim SF & Zelis R (Eds) Calcium blockers, pp. 137–152, Urban and Schwarzenberg, Baltimore, 1982

    Google Scholar 

  • Turner TJ, Goldin SM. Calcium channels in rat synaptosomes: Identification and pharmacological characterization: high affinity blockade by organic Ca2+channel blockers. Journal of Neuroscience 5: 841–849, 1985

    PubMed  CAS  Google Scholar 

  • Walsh TL, Lavenstein B, et al. Calcium antagonists in the treatment of Tourette’s disorder. American Journal of Psychiatry 143: 1467–1468, 1986

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, 3rd School of Medicine, Charles University, Šrobárova 48, 100 42, Praha 10, Czechoslovakia

    Cyril Höschl

  2. Psychiatric Center, Prague, Czechoslovakia

    Cyril Höschl

Authors
  1. Cyril Höschl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Höschl, C. Do Calcium Antagonists Have a Place in the Treatment of Mood Disorders?. Drugs 42, 721–729 (1991). https://doi.org/10.2165/00003495-199142050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199142050-00001

Keywords

Search

Navigation